Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. Khoury, R; Grimley, MS; Nelson, AS; Leemhuis, T; Cancelas, JA; Cook, E; Wang, YZ; Heyenbruch, D; Bollard, CM; Keller, MD; Hanley, PJ; Lutzko, C; Pham, G; Davies, SM; Rubinstein, JD. American Journal of Transplantation. 2024; 24:1634-1643.

COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report. McDonnell, J; Cousins, K; Younger, ME M; Lane, A; Abolhassani, H; Abraham, RS; Al-Tamemi, S; Aldave-Becerra, JC; Al-Faris, EH; Alfaro-Murillo, A; Lim, XR; Lopes, JP; López, AL; Tarquini, L. Journal of Clinical Immunology. 2024; 44:86.

Viral specific T cell therapy in kidney transplant recipients - A single-center experience. Anand, M; Nysather, J; McGraw, G; Apewokin, S; Khoury, R; Grimley, MS; Bumb, S; Govil, A. Transplant Infectious Disease. 2023; 25:e14179.

Viral-specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story. Montiel-Esparza, R; Michalak, SM; Le, AH D; Or, C; Nguyen, QD; Khoury, R; Grimley, MS; Bertaina, A; Klinger, E; Shah, AJ; Wood, EH. Pediatric Blood and Cancer. 2023; 70:e30429.

Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. Phillips, CL; Krupski, C; Khoury, R; Dandoy, CE; Nelson, AS; Galletta, TJ; Faulhaber, A; Davies, SM; Rubinstein, JD. 2023; 2:1151744.

Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Galletta, TJ; Rubinstein, JD; Krupski, C; Nelson, AS; Khoury, R; Dandoy, CE; Davies, SM; Phillips, CL. Pediatric Blood and Cancer. 2023; 70:e30271.

Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Galletta, TJ; Lane, A; Lutzko, C; Leemhuis, T; Cancelas, JA; Khoury, R; Wang, YZ M; Hanley, PJ; Keller, MD; Bollard, CM; Davies, SM; Grimley, MS; Rubinstein, JD. Transplantation and Cellular Therapy. 2023; 29:305-310.

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Rubinstein, JD; Breese, EH; Krupski, MC; O'Brien, MM; Dandoy, CE; Mizukawa, B; Khoury, R; Norris, RE; Davies, SM; Phillips, CL. Transplantation and Cellular Therapy. 2023; 29:311.e1-311.e7.

Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia. Chihanga, T; Vicente-Muñoz, S; Ruiz-Torres, S; Pal, B; Sertorio, M; Andreassen, PR; Khoury, R; Mehta, P; Davies, SM; Lane, AN; Romick-Rosendale, LE; Wells, SI. Cancers. 2022; 14:2040.

477 Availability of Donor Derived Patient Specific Virus-Specific T-Cells (VSTs) Is Not Associated with Differences in Outcomes As Compared to Frontline Administration of Third Party Vsts for the Management of Viral Infections after Pediatric Hematopoietic Stem Cell Transplant. Galletta, TJ; Lane, A; Lutzko, CM; Leemhuis, T; Cancelas, JA; Khoury, R; Wang, YM; Hanley, PJ; Keller, MD; Bollard, CM; Davies, SM; Grimley, MS; Rubinstein, JD. Transplantation and Cellular Therapy. 2022; 28:s374-s375.